Navigation Links
Cardium Reports on Second Quarter 2008 Highlights and Financial Results
Date:8/11/2008

involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release pu
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
4. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
7. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
10. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HOUSTON , Dec. 22, 2014 Cyberonics, Inc. ... devices for the treatment and management of epilepsy, today announced ... Morgan Healthcare Conference on Wednesday, January 14, 2015, in ... , Cyberonics, President and Chief Executive Officer, will speak at ... presentation can be accessed by clicking on the Investor Relations ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated ... study of lonafarnib in patients with chronic hepatitis ... at the National Institutes of Health (NIH) Clinical ...  The double-blinded, randomized, placebo-controlled, dose ascending study evaluated ... and 200 mg twice daily for 28 days.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... 10 Inclinix, Inc., an,enrollment contract research organization ... today that it has received a patent,for its ... system that guides,interview questions during patient qualification for ... Inclinix advertises to recruit patients into clinical trials.,Respondents ...
... LC STAR nebulizer and,PRONEB Ultra II compressor ... (Nasdaq: ISPH ) second Phase 3 ... treatment. PARI reusable nebulizers are,considered the gold ... in,commercial sales including AstraZeneca,s Pulmicort Respules, Sepracor,s,Xopenex ...
Cached Medicine Technology:Inclinix Announces New Patent for Expert System Platform 2PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial 2
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in Abilene, ... Ferguson, Missouri unrest. Yisrayl starts his letter by showing the ... has only increased. , He continues in his letter ... is a very specific reason for mankind and covers those ... of rules, or Laws that if followed would ensure that ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... taking a traditional Indian remedy for piles known as Endopile ... test of the drug, following a complaint, had revealed harmful ... been recalled from the Singapore market. The HSA said the ... ,The complaint came from a hospital that had treated a ...
... acids is claimed to prevent more sudden deaths ... even implanted defibrillators according to US scientists.// ... compared such preventive strategies by food supplementation and ... 100,000 people that resembled the population of Olmsted ...
... in the US do not wash their hands properly.// ... had conducted the survey of 8,000 people in eight countries. ... around U.S., U.K., Italy, Germany, United Arab Emirates, India, Malaysia, ... disinfectants, mouthwash, and cleaning products. In their survey they had ...
... and made available on the World Wide Web - a ... in the body. // ,The researchers had earlier identified ... surface of cells called cilia as such a common link. ... have links associated with the tiny, hair-like cilia and implications ...
... The State University of New Jersey have modified a ... stroke patients. The game helps with hand// exercises and ... effective that similar systems, which are more expensive. The ... stroke rehabilitation. ,Virtual rehabilitation gives therapists new ...
... St. Louis and other institutions have reported that experimental ... (PXR) my help in the treatment of Niemann-Pick type ... that is often fatal within the first two decades ... model for Niemann-Pick type C (NPC) disease showed that ...
Cached Medicine News:Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 3Health News:Stroke Rehabilitation Through Modified Video Games 2Health News:Drugs Activating PXR May Help In Treating Niemann-Pick type C disease 2Health News:Drugs Activating PXR May Help In Treating Niemann-Pick type C disease 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: